The company sold 10 million new shares at NOK 8.00 each: 9.3 million in the private placement and about 665,000 in a retail offering through Nordnet. Investors included Saturn Invest, HIFO Invest, TAJ Holding, Jakob Hatteland Holding and Per Strand Eiendom. The offering dilutes existing shareholders by about 12 percent, and Lytix plans a subsequent offering of up to NOK 15 million at the same price.

Besides Phase III preparations, the proceeds will cover Lytix’s share of the investigator-led ALETTA Phase II study, which tests ruxotemitide with ipilimumab and nivolumab, and advance the next-generation molecule LTX-401 toward Phase I. The Phase III study itself will require further financing and/or a partner.

“The proceeds allow us to prepare for a registrational Phase III study of ruxotemitide in neoadjuvant melanoma,” says Øystein Rekdal, CEO of Lytix Biopharma.